Group 1 - The core viewpoint of the article is that Gan Li Pharmaceutical has entered into a research collaboration with Jingtai Technology to develop innovative AI peptide drugs for metabolic diseases [1] - The agreement allows Gan Li Pharmaceutical to utilize Jingtai Technology's proprietary AI peptide research platform, PepiX™, to focus on unmet therapeutic needs in the field of metabolic diseases [1] - The collaboration aims to accelerate the discovery and development process of new peptide-based innovative drugs [1]